Document Detail

Immunohistochemical distributions of the tissue kallikrein-kinin system in ischemic and non-ischemic mouse heart.
MedLine Citation:
PMID:  14871029     Owner:  NLM     Status:  MEDLINE    
Kinins have been shown to play a cardioprotective role during myocardial ischemia. However, the localization of each of the components of the kallikrein-kinin system in the heart has not been determined in a cell type-specific manner. Recently, mK1 has been identified as the major tissue kallikrein with the strongest bradykinin-forming activity among the products of the mouse tissue kallikrein gene superfamily. In the study presented here, we investigated the localizations of mK1, kininogen and bradykinin B2 receptors (B2Rs) in ischemic and non-ischemic left ventricles by immunohistochemistry. Kininogen, which contains bradykinin as a surface epitope, was detected by an anti-bradykinin antibody. Changes in the amounts of mK1 and B2R were evaluated by Western blot analysis. Myocardial ischemia was induced by ligation of the left anterior descending coronary artery for 60 min followed by reperfusion for 24 h. mK1 and B2Rs were most abundantly expressed in the vascular endothelium and, to a lesser extent, in fibroblasts. No immunohistochemical signal of these molecules was detected in myocytes. Kininogen was localized in the vascular endothelium and the smooth muscle layer. Myocardial ischemia, although it had no effect on the localization of these molecules, increased the amounts of mK1 and B2R. We have obtained immunohistochemical evidence that all components of the tissue kallikrein-kinin system are present in the mouse heart. The coronary artery is the major site of kallikrein-kinin activity both in ischemic and non-ischemic hearts.
Yoko Yano; Ryoji Ozono; Hidekatu Nakashima; Yoshihiko Oishi; Masayuki Kambe; Kazuo Hosoi; Tetsuya Oshima
Related Documents :
9722349 - Ischaemic preconditioning: a clinical perspective.
10993769 - Transgenic overexpression of cardiac a(1) adenosine receptors mimics ischemic precondit...
19608979 - Hydrogen sulfide mediates cardioprotection through nrf2 signaling.
19445059 - Nuclear factor-[kappa]b inhibition provides additional protection against ischaemia/rep...
20156849 - Effects of substitution of cx43 by cx32 on myocardial energy metabolism, tolerance to i...
8069039 - Enhanced preservation of acutely ischemic myocardium using glucose-insulin-potassium so...
22412239 - Spontaneous right coronary artery dissection: causing myocardial infarction in a 36-yea...
19717959 - Persistent atrial standstill and idioventricular rhythm in a patient with thalassemia i...
1519519 - Doppler echocardiographic patterns of left ventricular filling in patients early after ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  42 Suppl 1     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2003 Dec 
Date Detail:
Created Date:  2004-02-11     Completed Date:  2004-03-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S49-53     Citation Subset:  IM    
Department of Clinical Laboratory Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blotting, Western
Bradykinin / biosynthesis,  immunology,  pharmacokinetics
Coronary Vessels / enzymology
Endothelium, Vascular / enzymology
Epitopes / immunology,  metabolism
Heart Ventricles / enzymology,  immunology,  ultrastructure
Immunoenzyme Techniques
Kallikrein-Kinin System / immunology*
Kininogen, High-Molecular-Weight / immunology,  metabolism
Kininogen, Low-Molecular-Weight / immunology,  metabolism
Mice, Inbred C57BL
Myocardial Ischemia / enzymology*,  immunology,  physiopathology
Receptor, Bradykinin B2 / drug effects,  immunology,  ultrastructure
Time Factors
Tissue Kallikreins / biosynthesis,  genetics,  metabolism*
Reg. No./Substance:
0/Epitopes; 0/Kininogen, High-Molecular-Weight; 0/Kininogen, Low-Molecular-Weight; 0/Receptor, Bradykinin B2; 58-82-2/Bradykinin; EC 3.4.21.-/mK1 protein, mouse; EC Kallikreins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Rho-kinase inhibition reduces neointima formation after vascular injury by enhancing Bax expression ...
Next Document:  Converting enzyme inhibitor temocaprilat prevents high glucose-mediated suppression of human aortic ...